vimarsana.com
Home
Live Updates
PHARNEXT: Pharnext refocuses its clinical trial programs on
PHARNEXT: Pharnext refocuses its clinical trial programs on
PHARNEXT: Pharnext refocuses its clinical trial programs on PXT3003, its most promising drug candidate, to optimize financial resources allocation
PARIS, France, February 14th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative
Related Keywords
United States ,
Paris ,
France General ,
France ,
Dennis Riedl ,
Mary Jane Elliott ,
Fabreguettes Leib ,
Deborah Schwartz ,
Hugo Brugi ,
Alexandra Harrison ,
Sukaina Virji ,
Financial Press Relations ,
Relations International ,
Company Board Of Directors ,
Consilium Strategic Communications ,
Amyotrophic Lateral Sclerosis ,
Euronext Growth ,
Neuroscience Res ,
Pharnext ,
Refocuses ,
Linical ,
Trial ,
Programs ,
Xt3003 ,
Most ,
Romising ,
Drug ,
Candidate ,
Optimize ,
Financial ,
Resources ,
Allocation ,